Expectant management of early onset, severe pre-eclampsia: Maternal outcome
dc.contributor.author | Hall D.R. | |
dc.contributor.author | Odendaal H.J. | |
dc.contributor.author | Steyn D.W. | |
dc.contributor.author | Grove D. | |
dc.date.accessioned | 2011-05-15T16:15:47Z | |
dc.date.available | 2011-05-15T16:15:47Z | |
dc.date.issued | 2000 | |
dc.description.abstract | Objective. To evaluate the safety and outcome of women undergoing expectant management of early onset, severe pre-eclampsia. Design. Prospective case series extending over a five-year period. Setting. Tygerberg Hospital, a tertiary referral centre. Population. All women (n = 340) presenting with early onset, severe pre-eclampsia, where both the mother and the fetus were otherwise stable. Methods. Frequent clinical and biochemical monitoring of maternal status, together with careful blood pressure control, in a high care obstetric ward. Main outcome measures. Major maternal complications and prolongation of gestation. Results: Multigravid women constituted 67% of the group. Antenatal biochemistry was reassuring with some expected, but not severe, deteriorations. Twenty-seven percent of women experienced a major complication, but few had poor outcomes. No maternal deaths occurred. Most major complications resolved quickly, necessitating only three admissions (0.8%) to the intensive care unit. One woman required dialysis. Pregnancies were prolonged by a mean (median) number of 11 days (9) before delivery, with more time being gained at earlier gestations. The postpartum inpatient stay (89% ≤ 7 days, bearing in mind that 82% of women were delivered by caesarean section) was not extended. Conclusion. Careful noninvasive management of early onset, severe pre-eclampsia in a tertiary centre can diminish and limit the impact of serious maternal complications. Valuable time to prolong the pregnancy and improve neonatal outcome is thereby gained. | |
dc.description.version | Article | |
dc.identifier.citation | British Journal of Obstetrics and Gynaecology | |
dc.identifier.citation | 107 | |
dc.identifier.citation | 10 | |
dc.identifier.issn | 03065456 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/13492 | |
dc.subject | article | |
dc.subject | blood pressure regulation | |
dc.subject | female | |
dc.subject | fetus distress | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | human tissue | |
dc.subject | major clinical study | |
dc.subject | onset age | |
dc.subject | patient monitoring | |
dc.subject | preeclampsia | |
dc.subject | priority journal | |
dc.subject | treatment outcome | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Antihypertensive Agents | |
dc.subject | Calcium Channel Blockers | |
dc.subject | Dihydralazine | |
dc.subject | Female | |
dc.subject | Fetal Distress | |
dc.subject | Human | |
dc.subject | Magnesium Sulfate | |
dc.subject | Methyldopa | |
dc.subject | Monitoring, Physiologic | |
dc.subject | Nifedipine | |
dc.subject | Prazosin | |
dc.subject | Pre-Eclampsia | |
dc.subject | Pregnancy | |
dc.subject | Pregnancy Outcome | |
dc.subject | Prospective Studies | |
dc.subject | Support, Non-U.S. Gov't | |
dc.title | Expectant management of early onset, severe pre-eclampsia: Maternal outcome | |
dc.type | Article |